Amylin (AMLN) Says SYMLIN + Insulin Gives Better Blood Glicose Measurement Results in Type 1, 2 Diabetes
Tweet
Share
E-mailGet Alerts AMLN Hot Sheet
Join SI Premium – FREE
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) announced results from new analyses of previously completed clinical studies demonstrating that patients with type 2 or type 1 diabetes achieved a greater proportion of blood glucose measurements in the normal range when SYMLIN (pramlintide acetate) injection treatment was used along with insulin. Two abstracts highlighting the analyses evaluated the proportion of readings from self-monitored seven-point glucose profiles that fell above, below or within glycemic targets based on guidelines set by the American Diabetes Association (ADA) and American Association of Clinical Endocrinologists (AACE). The data analyses are being presented at the 72nd Scientific Sessions of the ADA in Philadelphia.
“These results showed that SYMLIN, when used with mealtime insulin, helped patients maintain their blood sugar in the normal glucose range on a daily basis,” said David Maggs, M.D., vice president, medical research and development, Amylin Pharmaceuticals. “These data provide a ‘real-world’ analysis into the management of daily glucose levels as many patients, whether they have type 1 or type 2 diabetes, struggle to maintain target blood glucose levels despite treatment with mealtime insulin. Recognizing the important role it plays in helping patients control blood sugar at mealtime, ADA/EASD included SYMLIN in their new position statement on the treatment of hyperglycemia.”
In April of this year, the ADA and the European Association for the Study of Diabetes (EASD) published a new Position Statement on the management of hyperglycemia in type 2 diabetes. The Position Statement included key clinical considerations for the use of SYMLIN, reaffirming its use in conjunction with mealtime insulin to decrease post-meal glucose excursions.
“These results showed that SYMLIN, when used with mealtime insulin, helped patients maintain their blood sugar in the normal glucose range on a daily basis,” said David Maggs, M.D., vice president, medical research and development, Amylin Pharmaceuticals. “These data provide a ‘real-world’ analysis into the management of daily glucose levels as many patients, whether they have type 1 or type 2 diabetes, struggle to maintain target blood glucose levels despite treatment with mealtime insulin. Recognizing the important role it plays in helping patients control blood sugar at mealtime, ADA/EASD included SYMLIN in their new position statement on the treatment of hyperglycemia.”
In April of this year, the ADA and the European Association for the Study of Diabetes (EASD) published a new Position Statement on the management of hyperglycemia in type 2 diabetes. The Position Statement included key clinical considerations for the use of SYMLIN, reaffirming its use in conjunction with mealtime insulin to decrease post-meal glucose excursions.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Kimbell Royalty closes $221.2M mineral rights acquisition
- Denarius Metals acquires 15% stake in Copper Giant, Trafigura invests
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
